Kenneth Chang
Ophthalmology · Honolulu, HINPI 1134236821
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,814 of the $13,789 with a category attached, or 78.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations.
Across 241 payments — averaging $57.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- AbbVie$1K
- Sight Sciences, Inc.$1K
- Bausch & Lomb Americas Inc.$720
- Dompe US, Inc.$543
- plus $5K from 17 others
What the payments were for
- Consulting fees$2,13215%
- Travel & lodging$50%
- Food & beverage$10,81478%
- Other$8386%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 42 | $3,150 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $2,605 |
| AbbVie(2 entities) | 45 | $1,221 |
| Sight Sciences, Inc. | 18 | $1,000 |
| Bausch & Lomb Americas Inc. | 13 | $720 |
| Dompe US, Inc. | 10 | $543 |
| Genentech USA, Inc. | 13 | $529 |
| Amgen(2 entities) | 12 | $468 |
| NEW World Medical,inc. | 1 | $438 |
| Mallinckrodt Hospital Products Inc. | 8 | $374 |
| Regeneron Healthcare Solutions, Inc. | 4 | $368 |
| Rxsight Inc | 4 | $339 |
| Glaukos Corporation | 4 | $321 |
| Oyster Point Pharma, Inc. | 8 | $304 |
| Tarsus Pharmaceuticals, Inc. | 13 | $303 |
| Aerie Pharmaceuticals, Inc. | 10 | $303 |
| Sun Pharmaceutical Industries Inc. | 8 | $271 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $167 |
| Apellis Pharmaceuticals, Inc. | 1 | $112 |
| AstraZeneca | 4 | $99 |
| Novartis | 4 | $92 |
| Harrow Eye, LLC | 1 | $42 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,132
- Unity$983
- OMNI(R) SURGICAL SYSTEM (US)$713
- Clareon$538
- Rocklatan$486
- enVista MX60 IOL$423
- Hydrus Microstent$417
- Oxervate$379
- ENVISTA ENVY IOL$275
- VABYSMO$275
- TEPEZZA$260
- RXSIGHT CONTACT LENS$243
- RXSIGHT INJECTOR CARTRIDGE$243
- RXSIGHT INJECTOR HANDPIECE$243
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$243
- LIGHT ADJUSTABLE LENS (LAL)$243
- ACTHAR$240
- Rhopressa$235
- DURYSTA$234
- iStent Trabecular Micro-Bypass System Model iS3$153
How this compares
$13,789 in reported general payments places this provider in the 85th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 84 | $78,260 |
| RocklatanNetarsudil Mesylat/Latanoprost | 62 | $39,888 |
| VyzultaLatanoprostene Bunod | 33 | $23,281 |
| XdemvyLotilaner | 12 | $23,195 |
| XiidraLifitegrast | 16 | $16,386 |
| LumiganBimatoprost | 20 | $15,972 |
| CequaCyclosporine | 11 | $11,744 |
| TyrvayaVarenicline Tartrate | 15 | $10,017 |
| Azelastine Hcl | 156 | $5,183 |
| Prednisolone Acetate | 129 | $4,434 |
| Cyclosporine | 23 | $4,305 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,571 |
| Latanoprost | 185 | $3,460 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 233 | $3,281 |
| MoxifloxacinMoxifloxacin Hcl | 75 | $2,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,221 | $94,232104 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $303 | $39,88862 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $720 | $39,66849 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $303 | $23,19512 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $271 | $11,74411 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $304 | $10,01715 claims |
| AlconSimbrinza | $3,150 | $3,57115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.